RxDoctor Payments Data

Americo Baca, MD

Family Medicine · San Juan, TXNPI 1336168129

Payments from drug & device makers

$849in general payments, 2019–2025

Across 38 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$333
  • AstraZeneca$256
  • Lilly USA, LLC$136
  • Novartis$45
  • Bayer$40
  • AbbVie$23
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$849100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK24$333
AstraZeneca(2 entities)4$256
Lilly USA, LLC3$136
Novartis2$45
Bayer2$40
AbbVie2$23
Merck1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$849 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$22,331
Medicare patients
43
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide116$134,593
KerendiaFinerenone68$86,689
Trelegy ElliptaFluticasone/Umeclidin/Vilanter85$54,700
ProliaDenosumab24$40,732
TrulicityDulaglutide26$38,288
EntrestoSacubitril/Valsartan18$31,600
MyrbetriqMirabegron35$29,757
EliquisApixaban21$22,431
LinzessLinaclotide16$20,897
FarxigaDapagliflozin Propanediol25$19,465
MounjaroTirzepatide12$19,319
JanuviaSitagliptin Phosphate15$15,343
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$10,620
Lantus SolostarInsulin Glargine,hum.Rec.Anlog75$9,165
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$7,620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$40$86,68968 claims
Lilly USA, LLCTrulicity, Mounjaro$136$57,60838 claims
GSKTrelegy Ellipta$333$54,70085 claims
NovartisEntresto$45$31,60018 claims
AstraZenecaFarxiga, Breztri Aerosphere$256$30,08543 claims
AbbVieLinzess, Synthroid$23$23,37535 claims
MerckJanuvia$16$15,34315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Juan

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →